The global thrombopoietin receptor market is expected to rise at a considerable CAGR during the forecast period. Increasing prevalence of the disease is projected to drive the market growth during the forecast period. Frequent awareness activities by ITP support associations in the developed countries have been pivotal in making the masses aware about the disorder which could further fuel the market growth. Moreover, increasing investments for thrombopoietin receptor agonists (TPO-RAs) research and development in order to invent sophisticated technology that helps in enhancing the drug performance is anticipated to drive the market growth in the coming few years. The drug approvals by the regulatory authorizes has paved the path for new opportunities. Apart from these, the market players are also expanding their business in order to commercialize their products. For instance, in January 2022, Takeda Pharmaceutical Co acquired Adaptate Biotherapeutics a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (V?1) gamma delta (??) T cells. Through this acquisition, Takeda acquired Adaptate’s antibody-based ?? T cell engager platform, including pre-clinical candidate and discovery pipeline programs.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/thrombopoietin-receptor-market
Besides, in September 2021, Takeda Pharmaceutical Company Limited and JCR Pharmaceuticals Co., Ltd. announced geographically-focused exclusive collaboration and license agreement to commercialize JR-141. It is a next-generation recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase (IDS) enzyme for the treatment of Mucopolysaccharidosis type II or MPS II. Moreover, in September 2021, Grifols one of the world’s top three producers of plasma-derived medicines announced the availability of TAVLESSE® (fostamatinib) in France, Italy and Spain.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
o By Type
o By Application
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- including Novartis International AG, Amgen Inc., GlaxoSmithKline plc, 3SBio, Inc., AkaRx, Inc., and others.
Key questions addressed by the report
- What is the market growth rate?
- That segment and region dominate the market in the base year?
- That segment and region will project the fastest growth in the market?
- How does COVID-19 impact the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Thrombopoietin Receptor Market Report by Segment
By Type
- Eltrombopag Olamine
- GSK-2285921
- Romiplostim
- STST-4
- Others
By Application
- Clinic
- Hospital
- Others
A full report of Thrombopoietin Receptor Market is available at: https://www.omrglobal.com/industry-reports/thrombopoietin-receptor-market
Thrombopoietin Receptor Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Intas Pharmaceuticals Ltd.
- Rigel Pharmaceuticals, Inc.
- Shionogi & Co., Ltd.
- STATegics Inc.
- AkaRx Inc
- 3SBio Inc
